DNA RNA and Cells
1 March 2023
Verismo Therapeutics Announces $7 Million Pre-Series A with BRV Capital Management as Lead Investor27 February 2023
Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 202324 February 2023
FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection23 February 2023
Forge Biologics Reports Positive FBX-101 Clinical Updates for Patients with Krabbe Disease at WORLDSymposium23 February 2023
Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease22 February 2023
Resalis Therapeutics Announces Seed Financing of €10 Million to Fund Non-coding RNA-based Therapeutics for Metabolic Diseases21 February 2023
Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives21 February 2023
First Gene Therapy for Hemophilia B, CSL’s HEMGENIX®, Approved by the European Commission17 February 2023
Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium16 February 2023
GAIA BioMedicine and TreeFrog Therapeutics Announce Collaboration for the Expansion of Allogeneic NK-like Cells Against Solid Tumors16 February 2023
Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 ResultsNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports